Premium
Platelet‐activating factor and arachidonic acid metabolites in psoriatic inflammation
Author(s) -
IZAKI S.,
YAMAMOTO T.,
GOTO Y.,
ISHIMARU S.,
YUDATE F.,
KITAMURA K.,
MATSUZAKI M.
Publication year - 1996
Publication title -
british journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.304
H-Index - 179
eISSN - 1365-2133
pISSN - 0007-0963
DOI - 10.1046/j.1365-2133.1996.d01-902.x
Subject(s) - psoriasis , platelet activating factor , medicine , thromboxane b2 , leukotriene b4 , palmoplantar pustulosis , arachidonic acid , thromboxane , platelet , endocrinology , gastroenterology , inflammation , chemistry , immunology , enzyme , biochemistry
Summary Platelet‐activating factor (PAF). as wel as PAF acetylhydrolase (PAF‐AH) activity in the peripheral blood plasma of patients with psoriasis and palmoplantar pustolosis, was measured with a radio‐immunoassay technique, and compared with leukotriene (LT) B 4 . LTC 4 . LTD 4 , and E 4 , (LTD 4 /E 4 ). thromboxane (TX) B 2 and prostaglandin (PG) E 2 levels. In a normal healthy group ( n= 1 2) PAF level was 25.9 ± 6.5 pg/0.1 ml plasma (mean ± standard error of the mean: SEM). and this was elevated in patients with psoriasis (68.1 ± 11.8, n = 25. P <0.01), without a change in the PAF‐AH level. LTB 4 showed a similar increase (115.0 ± 21.6 pg/ml vs. 68.2 ± 11.8 pg/ml. P < 0.05), while TXB 2 , and PGE 2 showed insignificant ( P > 0.05) changes. LTC 4 and LTE 4 /E 4 were around the level of the limit of detection. Patients with palmoplantar pustulosis ( n = 33) demonstrated similar, but milder and statistically insignificant, increases in PAF. LTB 4 . TXB 2 and PGF 2 levels. Modulation of the mediator levels before and after treatment was compared in 16 patients with psoriasis and 11 with palmoplantar pustulosis. PAF in psoriasis significantly decreased after treatment (70.9 ± 17.1 to 25.1 ± 5.5, P < 0.05) and this was moderately correlated ( r = 0.298) with clinical improvement as indicated by the psoriasis area and severity index (38.5 ± 7.5 to 10.9 ± 4.2. P < 0.01). TXB 2 . (180.2 + 100.4 to 34.1 ± 13.5). PGF 2 (3.7 ± 0.7 to 2.9 ± 0.5) and LTB 4 (120.1 + 31.1 to 84.2 + 8.2). in psoriasis, mildly decreased without statistical significance. Patients with palmoplantar pustulosis demonstrated a similar decrease in all mediators without statistical significance. The results obtained suggest a role of PAF in psoriasis. As the priming effects of PAF have been shown, for leucocytes and endothelial cells, to enhance their inflammatory response, we assume that PAF has roles in the acute phase of osoriatic and leucotactic inflammation.